Definitive Contract 75N93023C00001
Award Date
11/1/22
Potential Completion Date
10/31/25
Potential Value
$14M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Microbiotix, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Worcester, MA 01605, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
This is a $5,057,523.60 definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract, which is not set-aside, supports the development of novel small molecule anti-infective drugs, with a focus on addressing unmet medical needs in infectious diseases. Microbiotix has received numerous federal contract and grant awards from agencies such as the National Institutes of Health (NIH) and the Department of...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (doing business as Forge Therapeutics) to develop a first-in-class LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This contract was awarded under a Broad Agency Announcement (BAA) that sought proposals for advanced development of vaccine...
This is a $2,594,319.91 federal contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of novel small molecule therapeutics to treat infections by Ebola and Marburg viruses. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a period of performance ending on December 14, 2020. Microbiotix has subcontracted with the Albert Einstein College of Medicine...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $548,977.00 cost-plus-fixed-fee contract is for the delivery of services in support of NIAID's infectious disease research and product development initiatives. This award is a task order under an existing Indefinite...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. government, has awarded a $306,500.00 firm fixed price definitive contract to Fox Chase Chemical Diversity Center Inc., a for-profit pharmaceutical organization. The contract, which does not have a set-aside designation, is for SBIR Topic 134 and has an ultimate completion date of November 14, 2025. Fox Chase Chemical Diversity Center Inc. is an experienced federal contractor, having received...
This is a $26,427,820.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Revagenix Inc. The contract is for the advanced development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. This contract was awarded under a Broad Agency Announcement (BAA) solicitation that sought proposals for research and development of vaccines, therapeutics, and diagnostics...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Phase II contract to Nowdiagnostics, Inc., a small disadvantaged business, for a multiplexed remote system for filovirus disease surveillance. The firm-fixed-price contract, with a potential value of $2,431,860.00, was awarded on September 20, 2018 and has a completion date of September 30, 2022....